DS Healthcare Group Expands its Distribution Channels in $43 Billion Brazilian Beauty Market
Pompano Beach, Aug. 5, 2013 (GLOBE NEWSWIRE) -- DS Healthcare Group, Inc. (NASDAQ:DSKX), a leading developer of personal care products, today announced it has expanded the distribution of its product lines into Brazil's CSB Drogaria which operates two retail pharmacy chains, Drogasmil and Farmalife, which together have 85 retail store locations. The stores are primarily located in the Rio de Janeiro metropolitan area. CSB Drogaria is owned by Profarma, a leader in the distribution to pharmacies, distributing 18 million units per month, through 31,000 sales outlets, covering 93% of the consumer market for pharmaceutical products in Brazil.
DS Healthcare Group is expected to experience rapid sales increases in Brazil, as its established distribution there grows.
"Our 10 best-selling SKUs which are approved for commercialization and distribution are currently being sold in the Brazilian market. This includes our leading hair loss products. We plan on receiving further regulatory approvals as sales begin to accelerate. We are working with a fantastic partner there and are excited about this new relationship. Based on the success of this pilot program, we expect to continue to expand throughout Profarma's network, one of the biggest distributors in Brazil. We believe our products have a considerable advantage to anything currently being sold in Brazil," stated DS Healthcare President and CEO Daniel Khesin.
According to Euromonitor, a market research firm, the Brazilian beauty industry generated $43 billion in sales in 2011, an increase of 19% over the prior year.
About DS Healthcare Group
DS Healthcare Group Inc. leads in the development and distribution of topical therapies for personal care, including what management believes is the world's most effective topical treatment for hair loss. Its products are sold through a network of salons, online retailers, specialty retailers and selected department stores. Its brands include DS Laboratories (www.DSLaboratories.com), Sigma Skin (www.(www.SigmaSkin.com), Polaris Research Laboratories (www.PolarisReserachLabs.com), The Pure Guild (www.ThePureGuild.com) and Nutra Origin (www.NutraOrigin.com)
Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies, and are generally preceded by words such as "future," "plan" or "planned," "expects," or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing and marketing products, intense competition, and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available at www.sec.gov.
CONTACT: Contact: Laurel Moody Corporate Profile 1.646.810.0608 Source:DS Healthcare Group,Inc.